Modulating specific fibrinolytic components—such as enhancing Plg activation or inhibiting α2AP—may offer novel therapeutic strategies to mitigate disease severity and reduce thrombotic risk in SLE. The gene discussed is PLG; the disease is systemic lupus erythematosus.